StreetAlpha.app
Home › Stocks › CRMD

CorMedix Inc. (CRMD)

Healthcare
$4.67
▼ −3.11%
LAST CLOSE · NOV 17

CorMedix develops and sells DefenCath, a catheter lock solution for dialysis patients, plus hospital infection drugs and a heart medicine. It last closed at $4.67 on Nov 17, down 3.11% on the day. The average 12-month price target from 3 analysts is $13.33 (+185.5% from the last close), with a high of $15.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $237K, the largest $237K.

AI Auto Pilots
Is CRMD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$412.5M
+92.5% vs a year ago
Net income
$63.9M
−60.7% vs a year ago
EPS (diluted)
$0.64
−71.0% vs a year ago
Free cash flow
$307.9M
74.6% margin
Valuation
Market cap
$371.4M
79.5M shares
P/E
7.3
Price over 12 month EPS
Price to sales
0.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$355.1M
At Sep 30
Shareholder equity
$461.7M
Shares outstanding
79.5M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $191K$191KFY2021FY2022: $65K$65KFY2022FY2024: $43.5M$43.5MFY2024FY2025: $311.7M$311.7MFY2025

From CRMD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on CRMD in the past 90 days
Average 12-month target
$13.33
▲ 185.5% upside

Based on 3 analysts who set a price target on CRMD in the past 90 days. The average target is $13.33, with a high of $15.00 and a low of $12.00, compared with the last close of $4.67.

Low $12.00Avg $13.33High $15.00
Blue marker: last close $4.67
Highest target$15.00
Average target$13.33
Lowest target$12.00
Latest rating changes
OppenheimerTarget lowered
Nov 13Buy$15 → $13
RBC CapitalMaintained
Nov 10Buy$15
NeedhamMaintained
Nov 2Buy$12
OppenheimerInitiated
Sep 23Buy$15
DateFirmActionRatingPrice target
Nov 13OppenheimerTarget loweredBuy$15 → $13
Nov 10RBC CapitalMaintainedBuy$15
Nov 2NeedhamMaintainedBuy$12
Sep 23OppenheimerInitiatedBuy$15
Loading…

Technical Analysis

CRMD · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 32% below its 20 day and 51% below its 50 day average. It is 61% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $4.63, and the nearest resistance the Pivot at $4.72.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.9%/day
Key levels
$13.0252 week high+178.8%
$7.66Swing high (Aug 4)+64.0%
$7.55100 day average+61.7%
$7.53200 day average+61.2%
$7.0450 day average+50.7%
$6.1820 day average+32.3%
$4.81Pivot R1+3.0%
$4.72Pivot+1.1%
$4.67Last close
$4.6352 week low−0.9%
$4.58Pivot S1−1.9%
Indicators
RSI (14)26.09Oversold below 30Oversold
MACD-0.74Below its signal lineBearish
Stochastic1.9Near the bottom of its rangeOversold
ADX (14)35.5Trending down
Williams %R-99.1Oversold below −80, overbought above −20Oversold
CCI (20)-84.9Oversold below −100, overbought above 100Neutral
Rate of change−16.0%Change over 10 sessionsBearish
ATR (14)$0.41Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRMD

What happened before

See how CRMD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CRMD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CRMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CRMD in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$237K
Largest print
$237K
Loading…

CRMD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●87 buying vs 89 selling
  • ▲Held by funds +3.2 pts
  • ▼Funds holding -7
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding188195−3.6%
In funds' top 1000–
Held by funds58.6%55.4%+3.2 pts
New / increased21 / 6627 / 68−8.4%
Reduced / sold out63 / 2658 / 21+12.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRMD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRMD is in one of them and how their past CRMD trades turned out.

CRMD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRMD in an article yet. Here's the latest on the wider market.

About CorMedix

CorMedix is a biopharmaceutical company based in Parsippany, New Jersey, that develops and sells drugs for serious medical conditions. Its main product is DefenCath, a catheter lock solution that helps reduce bloodstream infections in adult kidney failure patients who receive dialysis through a central venous catheter. Its customers are mainly outpatient dialysis clinics and hospitals. The company also sells a set of hospital-focused drugs for serious infections, including REZZAYO and VABOMERE, along with the heart drug TOPROL XL. These products are used in hospitals, emergency departments, outpatient clinics and home infusion care.

Headquarters
Parsippany, NJ